Dr. Reddy’s Laboratories announced the launch of Sumatriptan Injection Autoinjector System for Subcutaneous Use, the generic version of GlaxoSmithKline‘s Imitrex STATdose Pen.

Sumatriptan is a selective 5-HT1B/1D receptor agonist indicated for the acute treatment of migraine or cluster headaches. Sumatriptan is presumed to exert its therapeutic effects in the treatment of migraine headache by binding to 5-HT1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.

Dr. Reddy’s Sumatriptan Injection Autoinjector System is available in a 6mg/0.5mL strength as a carton containing 2 single-dose prefilled syringes.

For more information call (866) 733-3952 or visit DrReddys.com.